# EDGAR Filing Document

**Accession Number:** 0001002624
**File Stem:** 0001193125-23-044824
**Filing Date:** 2023-2
**Character Count:** 210299
**Document Hash:** ded5c2d45c5adf93f848eac9bb45b36f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-044824.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001193125-23-044824

**CONFORMED SUBMISSION TYPE**: N-CSR

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**EFFECTIVENESS DATE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** T. Rowe Price Health Sciences Fund, Inc.
- **CENTRAL INDEX KEY:** 0001002624
- **IRS NUMBER:** 521952906
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-CSR
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-07381
- **FILM NUMBER:** 23653211

**BUSINESS ADDRESS:**
- **STREET 1:** 100 EAST PRATT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21202
- **BUSINESS PHONE:** 410-345-2000

**MAIL ADDRESS:**
- **STREET 1:** 100 EAST PRATT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE HEALTH SCIENCES FUND INC
- **DATE OF NAME CHANGE:** 19980513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE HEALTH & LIFE SCIENCES FUND INC
- **DATE OF NAME CHANGE:** 19951023

## Series and Classes Contracts Data

### T. Rowe Price Health Sciences Fund, Inc. (Series ID: S000002088)

| Class ID   | Class Name                                 | Ticker Symbol   |
|:---|:---|:---|
| C000005456 | T. Rowe Price Health Sciences Fund, Inc.   | PRHSX           |
| C000169937 | T. Rowe Price Health Sciences Fund-I Class | THISX           |

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

# **FORM N-CSR**

# **CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES**

Investment Company Act File Number: 811-07381

T. Rowe Price Health Sciences Fund, Inc.
(Exact name of registrant as specified in charter)

100 East Pratt Street, Baltimore, MD 21202
(Address of principal executive offices)

David Oestreicher
100 East Pratt Street, Baltimore, MD 21202
(Name and address of agent for service)

Registrant's telephone number, including area code: (410) 345-2000

Date of fiscal year end: December 31

Date of reporting period: December 31, 2022

# ---**Item 1. Reports to Shareholders**

# **(a) Report pursuant to Rule 30e-1**

T.RowePrice®

# **ANNUAL REPORT**

December 31, 2022

| PRHSX | T. ROWE PRICE Health Sciences Fund |
| --- | --- |
| THISX | Health Sciences Fund- I Class |

INVEST WITH CONFIDENCE®

- The Health Sciences Fund outperformed its benchmark and the broad equity market in the 12 months ended December 31, 2022.

- Allocation effects drove outperformance, while stock selection detracted. The services and pharmaceuticals subsectors contributed the most to relative performance, while biotechnology and life sciences detracted.

## Go Paperless

Sign up for e-delivery of your statements, confirmations, and prospectuses or shareholder reports.

### TO ENROLL:

If you invest directly with T. Rowe Price, go to **troweprice.com/paperless**.

If you invest through an investment advisor, a bank, or a brokerage firm, please contact that organization and ask if it can provide electronic documentation.

**It's fast**-receive your statements and confirmations faster than U.S. mail.

**It's convenient**-access your important account documents whenever you need them.

**It's secure**-we protect your online accounts using 'True Identity' to confirm new accounts and make verification faster and more secure.

**It can save you money**-where applicable, T. Rowe Price passes on the cost savings to fund holders.*

* Certain mutual fund accounts that are assessed an annual account service fee can also save money by switching to e-delivery.

T. ROWE PRICE HEALTH SCIENCES FUND

Market Commentary

# **HIGHLIGHTS**

While we expect the macroeconomic backdrop to remain challenging in the near term, we maintain an optimistic outlook for the sector going forward.

We believe investors need to be selective, and we are staying due to our philosophy of investing in highly innovative therapeutic companies and companies that can improve the standard of care in a cost-effective manner, which has served us well over time.

Double-digit losses have common in equity markets around the world, and bond investors also faced a historically tough environment amid a sharp rise

Log in to your account at troweprice.com for more information.

T. ROWE PRICE HEALTH SCIENCES FUND

## Dear Shareholder

In interest rates Value shares declined but outperformed growth stocks by a market, with the Bloomberg U.S. Aggregate Bond Index delivering its worst considerable margin as equity investors turned risk averse and as rising rates year on record. (Bond prices and yields move in opposite directions.) Put downward pressure on growth stock valuations. Emerging markets stocks generally underperformed shares in developed markets. Meanwhile, U.S. debt strength and structure is strong, but the market is not yet a significant increase in the market's share. The U.S. debt strength and structure is strong, but the market is not yet a significant increase in the market's share. The U.S. debt strength and structure is strong, but the market is not yet a significant increase in the market's share.

1

T. ROWE PRICE HEALTH SCIENCES FUND

# Management's Discussion of Fund Performance

sharp increase in yields led to historically weak results across the fixed income
300% of the SAP 500 Index, energy was a rare bright spot, gaining more than

60% as oil prices jumped in response to Russia's invasion of Ukraine and
The past year has been a try by the new investors as few sectors remained
concerns over commodity supply shortages. Defensive shares, such as utilities,
untouched by the broad headwinds that markets faced and volatility may
consumer staples, and health care, held up relatively well and finished the
continue in the near term as central banks tighten policy amid slowing
year with roughly flat returns. Conversely, communication services, consumer
and information technology shares suffered the largest declines.
However, in our view, there continue to be opportunities for
discretionary and information technology shares suffered the largest declines.
selective investors focused on fundamentals. Valuations in most global equity
investment professionals, go to

troweprice.com.

|  | Total Return |  |
| --- | --- | --- |
| Periods Ended 12/31/22 | 6 Months | 12 Months |
| Health Sciences Fund | 6.60% | -12.19% |
| Health Sciences Fund- I Class | 6.67 | -12.08 |

2

T. ROWE PRICE HEALTH SCIENCES FUND

# **INVESTMENT OBJECTIVE**

The Health Sciences Fund returned -12.19% in the 12-month period ended March 31, 2022. The fund is supported by the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding of the Department of Health and Human Services. The Fund's funding is based on the funding

| S&P 500 Index | 2.31 | -18.11 |
| --- | --- | --- |
| Lipper Health/ Biotechnology Funds Index | 10.33 | -12.94 |

|  | Percent of Net Assets |  |
| --- | --- | --- |
|  | 6/30/22 | 12/31/22 |
| Biotechnology | 25.2% | 26.8% |
| Services | 24.3 | 23.6 |
| Pharmaceuticals | 17.3 | 18.0 |

3

T. ROWE PRICE HEALTH SCIENCES FUND

Conversely, stock picks in the biotechnology subsector detracted. The officials on how high rates would have to go. The Fed, which at the end of 2008, was the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first time of the first

An overweight exposure to life sciences, the worst performing study selection is the most important, but the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important, the most important

| Life Sciences | 15.8 | 15.9 |
| --- | --- | --- |
| Products and Devices | 16.6 | 14.7 |
| Consumer Nondurables | 0.6 | 0.2 |
| Other and Reserves | 0.2 | 0.8 |
| Total | 100.0% | 100.0% |

Historical weightings reflect current industry/sector

4

T. ROWE PRICE HEALTH SCIENCES FUND

biotechnology companies. Conversely, we have found opportunities to

investigate in the growth of the world's leading global market. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period.

The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period.

The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period.

The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period. The company's data is shown in the U.S. Treasury Note climbing from 1.52% at the start of the period to 2.69% at the end of the period.

classifications.

5

T. ROWE PRICE HEALTH SCIENCES FUND

The portfolio is overweight life sciences companies, which develop the

divergent, solid cash flow generation, and a strong internal research and
high interest rates, rising inflation, and growing recessionary fears weighing
international growth, the rising and becoming more than a half of the world
of the global economy. The market has been increased, and the
first to question respect in companies with a large and very large
retail. Challenging in the near term, the maintain of opiness, which is the
to ease profits and fund other higher-censored companies developing
the world. In addition, the call system is also a strong
health in response to cost inflation which invests in the
well-issued inflation and legal cost pressures as well as strong balance
We are seeing great progress across a number of
the companies that are responsible for the
including oncology, neurology, ophthalmology, and pathology
and the various from their more defensive characteristics. Given rising recession uncertainties

6

T. ROWE PRICE HEALTH SCIENCES FUND

# **RISKS OF GROWTH INVESTING**

tensive characteristics was another source of relative strength

F

# **TWENTY-FIVE LARGEST HOLDINGS**

|  | Percent of Net Assets |
| --- | --- |
|  | 12/31/22 |
| UnitedHealth Group | 8.7% |

7

T. ROWE PRICE HEALTH SCIENCES FUND

Thermo Health Sciences Fund is a member of the Department of Health and Human Services, a public health organization. The Fund is funded by the Department of Health and Human Services, a private health organization. The Fund is funded by the Department of Health and Human Services, a private health organization. The Fund is funded by the Department of Health and Human Services, a private health organization.

![img-0.jpeg](img-0.jpeg)

8

T. ROWE PRICE HEALTH SCIENCES FUND

# **GROWTH OF $10,000**

| Intuitive | Source | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Stocker | Health Sciences Fund | -12.19% | 11.08% | 15.91% | - | - | 2.3 |
| P |  |  |  |  |  |  |  |
| A |  |  |  |  |  |  |  |
| V | Periods Ended 12/31/22 | 1 Year | 5 Years | 10 Years | Since Inception | Inception Date |  |
| K | Health Sciences Fund | -12.19% | 11.08% | 15.91% | - | - |  |
| A | Health Sciences Fund- |  |  |  |  |  |  |
| B | I Class | -12.08 | 11.21 | - | 12.77% | 3/23/16 |  |

$5

9

T. ROWE PRICE HEALTH SCIENCES FUND

# AVERAGE ANNUAL COMPOUND TOTAL RETURN

| AbbVie Standard & Poor's Financial Services LLC, a division of S&P Global "S&P" |  | 1.7 |
| --- | --- | --- |
| Caution |  |  |
| A |  |  |
| IV | Health Sciences Fund | 0.75% |
| C |  |  |
| C | Health Sciences Fund-I Class | 0.65 |
| The views change to a forecast | The expense ratio shown is as of the fund's most recent prospectus. This number may vary from the expense ratio shown elsewhere in this report because it is based on a different time |  |

10

T. ROWE PRICE HEALTH SCIENCES FUND

# **EXPENSE RATIO**

FUND EXPENSE EXAMPLE

In the first two years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue (CAGR) for the first three years of a constant rate Average Annual Total Return Revenue

![img-1.jpeg](img-1.jpeg)

11

T. ROWE PRICE HEALTH SCIENCES FUND

# **FUND EXPENSE EXAMPLE (CONTINUED)**

when you are estimating the ongoing expenses of investing in the fund and when comparing the underlying costs (in dollars) of investing in the fund and to compare these costs with the ongoing costs of investing in other mutated funds. The example is based on an investment of $1,000 invested in the beginning of the most recent period, and the fund for the entire period. The table is used for the entire period.

# **Investor Class**

The table is useful in comparing ongoing costs only and will not share classes. The original share class (Investor Class) includes the most of the following: the first class of investing in the fund and the second class of investing in the fund. The first class of investing in the fund is based on an investment of $1,000 invested in the beginning of the most recent period, and the second class of investing in the fund is based on an investment of $1,000 invested in the beginning of the most recent period.

# **NET ASSET VALUE**

| Beginning of period | $104.08 | $98.85 | $81.43 | $67.01 | $70.35 |
| --- | --- | --- | --- | --- | --- |

# Investment activities

| Net investment income (loss) (1)(2) | (0.09) | (0.22) | (0.04) | - (3) | 0.04 |
| --- | --- | --- | --- | --- | --- |

12

T. ROWE PRICE HEALTH SCIENCES FUND

GRAND TOTAL - ПРИЛОЖЕНИЕ - separately in the table.

| Actual Expenses | For a share outstanding throughout each period |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| The first line of the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. You may use the information on the line, together with the following table (Actual) provides information about actual account values and expenses based on the fund's actual returns. Investor Class Account Value Account Value Discount Discount Discount Discount Account Value 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 Discount 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 Discount 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 |  |  |  |  |  |
| Investor Class |  |  |  |  |  |
| Account Value | Account Value | Discount | Discount | Discount | Discount |
| Account Value | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 |
| Discount | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 |
| Discount | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 |

| Total Investment Income |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Net realized gain | (1.59) | (7.76) | (7.08) | (4.98) | (4.40) |
| Total distributions | (1.59) | (7.76) | (7.08) | (4.98) | (4.40) |
| Total return on | (12.19)% | 13.27% | 30.12% | 29.11% | 1.23% |

13

T. ROWE PRICE HEALTH SCIENCES FUND

**FINANCIAL HIGHLIGHTS**
**Preliminary Example for Comparison Purposes**
(Return before expenses) 1,500.00 For a 1,500.00 outstanding throughout each period
The information on the second line of the table (Hypothetical) is based on hypothetical account
with the fund's actual expense ratio and an assumed 5% per year
rate/return before expenses (not the 1,500.00 actual return) may compare the ongoing 49

| Class | with other funds by contrasting this 5% hypothetical example |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 1,500.00 | 1,500.00 | 1,500.00 | 1,500.00 | 1,500.00 |
| Net expenses after waivers/ | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 |
| payments by Price Associates | 0.80% | 0.75% | 0.76% | 0.76% | 0.77% |
| NET ASSET VALUE |  |  |  |  |  |
| Net investment income (loss) | $104.55 | $98.87 | $81.42 | $67.50 | $70.34 |
| Beginning of period |  |  |  |  |  |
| Portfolio turnover rate | 28.8% | 33.8% | 41.7% | 38.8% | 43.0% |
| Investment activities |  |  |  |  |  |
| Net assets, end of period (in | 0.05 | (0.11) | 0.05 | 0.08 | 0.14 |
| Net investment income (loss) (1)(2) |  |  |  |  |  |

14

T. ROWE PRICE HEALTH SCIENCES FUND

December 31, 2022

**COMMON STOCKS** All to the fund's annualized expense ratio for the 6-month period, multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year (184), and divided by the days in the year (365) to reflect (Cost and value in $000s). The annualized expense ratio of the Investor Class was 0.80%, and

|  | $10,235 | $17,213 | $15,753 | $12,649 | $10,666 |
| --- | --- | --- | --- | --- | --- |
| COMMON STOCKS 94.2% |  |  |  |  |  |
| Net realized and unrealized gain/loss | (12.60) | 13.22 | 24.57 | 19.46 | 1.01 |
| BIOTECHNOLOGY 22.1% | (12.55) | 13.11 | 24.62 | 19.54 | 1.15 |
| Total from investment activities |  |  |  |  |  |
| International Biotechnology 0.0% |  |  |  |  |  |
| Per share amounts calculated using average shares outstanding method. |  |  |  |  |  |
| Debtors' total of expense-related arrangements with Price Associates 184,265 |  |  |  |  | 2,440 |
| Valuation of the funds less than $0.01 per share |  |  |  | (0.14) |  |
| Net realized gain | (1.59) | (7.92) | (7.17) | (4.96) | (4.49) |
| Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of its redemption for account fees, if applicable. | (1.59) | (7.92) | (7.17) | (4.96) | (4.49) |

15

T. ROWE PRICE HEALTH SCIENCES FUND

# **SCHEDULED OR INVESTMENTS**

|  | Shares | % Value |  |
| --- | --- | --- | --- |
| Major Biotechnology 4.9% (Cost and value in $000s) |  |  |  |
| Biogen (1) | 357,689 | 99,051 |  |
| Biocids, Therapeutics, ADR (1) | 254,670 | 7,128 |  |
| NET ASSET VALUE | 567,931 | 84,287 |  |
| Biocides, Therapeutics (1) | 1,123,065 | 29,127 |  |
| Exad. Sciences (1) | $89.91 | $104.05 | $98.87 |
| Exad. Sciences (1) | 1,123,065 | 29,127 | 4,621 |
| Synthesis, Pharmaceuticals, ADR (1) | 957,065 | 47,127 | 2,762 |
| Exad. Sciences, Food, Medicine, Acquisition, Date: 1/6/21 | 891,078 | 2,762 |  |
| Cerevel Therapeutics Holdings (1) | 1,633,045 | 51,506 |  |

# **Ratios/Supplemental Data**

| Total - return 100% | (12.08)% | 13.40% | 30.27% | 29.25% | 1.35% |
| --- | --- | --- | --- | --- | --- |

16

T. ROWE PRICE HEALTH SCIENCES FUND

| Cost ($) | 3,726,272 | 1,672 |
| --- | --- | --- |
| Excess Expenses (1) | 1,000,000 | 1,000,000 |
| Excess Expenses Expense Fund, Acquisition Date: 1/6/21, | 427,000 | 19,000 |
| Expenditures (1) | 4,705 | 4 |
| Cost ($) | 474,062 | 10,202 |
| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

| Excess Expenses (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1,071,059 | 29,786 |
| --- | --- | --- |

17

T. ROWE PRICE HEALTH SCIENCES FUND

| ECIRs, Warrants, 12/20/26 (1) | 1,427,620 | 187,816 |
| --- | --- | --- |
| Exeter, 25/19 (1) | 1,177,000 | 794,000 |
| Exeter, 25/19 (1) | 1,177,000 | 794,000 |
| Exeter, 25/19 (1) | 2,078,528 | 33,444 |
| Exeter, 25/19 (1) | 180,888 | 1,024 |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |
| Exeter, 25/19 (1) | 1,177,000 | 1,024 |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

| Exeter, 25/19 (1) | 1,177,000 | 1,024 |
| --- | --- | --- |

[{"box_2d": [30, 174, 614, 224], "label": "table", "caption": "

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

<table><td>Total</td><td>1,000,000</td><td>1,000</td></tr></table>

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

| Total | 1,000,000 | 1,000 |
| --- | --- | --- |

<

T. ROWE PRICE HEALTH SCIENCES FUND

| Proposed Revenue | 1,133,988 | 4,008 |
| --- | --- | --- |
| Proposed Revenue Fund, Acquisition Date: 9/12/22, Cost $12 (1) | 1,133,988 | 1,133,988 |
| Proposed Revenue Fund, Acquisition Date: 9/17/21, Cost $12,365 (1)(2)(3) | 1,133,988 | 1,133,988 |
| Proposed Revenue Fund, Acquisition Date: 9/17/21, Cost $- (1)(3) | 1,133,988 | 1,133,988 |
| Total Proposed Revenue | 2,017,398 | 7,147 |
| Proposed Revenue Fund, Acquisition Date: 9/12/22, Cost $- (1)(3) | 2,017,398 | 2,017 |
| Proposed Revenue Fund, Acquisition Date: 9/17/21, Cost $- (1)(3) | 2,017,398 | 13,474 |
| Proposed Revenue Fund, Acquisition Date: 9/17/21, Cost $- (1)(3) | 2,017,398 | 13,474 |
| Proposed Revenue Fund, Acquisition Date: 9/17/21, Cost $- (1)(3) | 2,017,398 | 13,474 |
| Proposed Revenue Fund, Allocation Date: 9/17/22, Cost $- (1)(3) | 2,017,398 | 13,474 |
| Proposed Revenue Fund, Allocation Date: 9/17/22, Cost $- (1)(3) | 2,017,398 | 13,474 |
| Proposed Revenue Fund, Allocation Date: 9/17/22, Cost $- (1)(3) | 2,017,398 | 13,4 |

19

T. ROWE PRICE HEALTH SCIENCES FUND

| Respiratory Growth (1) | 1,377,000 | 30,000 |
| --- | --- | --- |
| Respiratory Growth (2) | 1,377,000 | 30,000 |
| Respiratory Growth (3) | 1,377,000 | 30,000 |
| Respiratory Growth (4) | 1,377,000 | 30,000 |
| Respiratory Growth (5) | 1,377,000 | 30,000 |
| Respiratory Growth (6) | 1,377,000 | 30,000 |
| Respiratory Growth (7) | 1,377,000 | 30,000 |
| Respiratory Growth (8) | 1,377,000 | 30,000 |
| Respiratory Growth (9) | 1,377,000 | 30,000 |
| Respiratory Growth (10) | 1,377,000 | 30,000 |
| Respiratory Growth (11) | 1,377,000 | 30,000 |
| Respiratory Growth (12) | 1,377,000 | 30,000 |
| Respiratory Growth (13) | 1,377,000 | 30,000 |
| Respiratory Growth (14) | 1,377,000 | 30,000 |
| Respiratory Growth (15) | 1,377,000 | 30,000 |
| Respiratory Growth (16) | 1,377,000 | 30,000 |
| Respiratory Growth (17) | 1,377,000 | 30,000 |
| Respiratory Growth (18) | 1,377,000 | 30,000 |
| Respiratory Growth (19) | 1,377,000 | 30,000 |
| Respiratory Growth (20) | 1,377,000 | 30,000 |

20

T. ROWE PRICE HEALTH SCIENCES FUND

| Information 0.9% | 1,000,000 | 266,000 |
| --- | --- | --- |
| Philippines, Pharmaceuticals, Class A (1) | 1,000,000 | 1,000,000 |
| Philippines, Food, Drugs (1) | 1,000,000 | 1,000,000 |
| Stark Pharmaceuticals (1) | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 1/23/19 | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 1/23/19 | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 1/23/19 | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 1/23/19 | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 1/23/19 | 1,000,000 | 1,000,000 |

| Reese Life Insurance, Series B, Acquisition Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |
| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Acquisition Date: 9/2/21, | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |
| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |
| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series A (1) | 1,000,000 | 1,000,000 |
| --- | --- | --- |

| Reese Life Insurance, Series B, Application Date: 9/2/21, | 1,000,000 | 1,000,000 |
| --- | --- | --- |

[{"box_2d": [311, 681, 332, 692], "label": "header_footer", "header_footer",box_ [BBOX]0,1,0,0,0.1,0,0,0.1[/BBOX] 21"}]

T. ROWE PRICE HEALTH SCIENCES FUND

| Wages (1) | 1,165,000 | 72,200 |
| --- | --- | --- |
| Wages (2) | 1,165,000 | 72,200 |
| Wages (3) | 1,165,000 | 72,200 |
| Wages (4) | 1,165,000 | 72,200 |
| Wages (5) | 1,165,000 | 72,200 |
| Wages (6) | 1,165,000 | 72,200 |
| Wages (7) | 1,165,000 | 72,200 |
| Wages (8) | 1,165,000 | 72,200 |
| Wages (9) | 1,165,000 | 72,200 |
| Wages (10) | 1,165,000 | 72,200 |
| Wages (11) | 1,165,000 | 72,200 |
| Wages (12) | 1,165,000 | 72,200 |
| Wages (13) | 1,165,000 | 72,200 |
| Wages (14) | 1,165,000 | 72,200 |
| Wages (15) | 1,165,000 | 72,200 |
| Wages (16) | 1,165,000 | 72,200 |
| Wages (17) | 1,165,000 | 72,200 |
| Wages (18) | 1,165,000 | 72,200 |
| Wages (19) | 1,165,000 | 72,200 |
| Wages (20) | 1,165,000 | 72,200 |
| Wages (21) | 1,165,000 | 72,200 |
| Wages (22) | 1,165,000 | 72,200 |
| Wages (23) | 1,165,000 | 72,200 |
| Wages (24) | 1,165,000 | 72,200 |
| Wages (25) | 1,165,000 | 72,200 |
| Wages (26) | 1,165,000 | 72,200 |
| Wages (27) | 1,165,000 | 72,200 |
| Wages (28) | 1,165,000 | 72,200 |
| Wages (29) | 1,165,000 | 72,200 |
| Wages (30) | 1,165,000 | 72,200 |
| Wages (31) | 1,165,000 | 72,200 |
| Wages (32) | 1,165,000 | 72,200 |
| Wages (33) | 1,165,000 | 72,200 |
| Wages (34) | 1,165,000 | 72,200 |
| Wages (35) | 1,165,000 | 72,200 |
| Wages (36) | 1,165,000 | 72,200 |
| Wages (37) | 1,165,000 | 72,200 |
| Wages (38) | 1,165,000 | 72,200 |
| Wages (39) | 1,165,000 | 72,200 |
| Wages (40) | 1,165,000 | 72,200 |
| Wages (41) | 1,165,000 | 72,200 |
| Wages (42) | 1,165,000 | 72,200 |
| Wages (43) | 1,165,000 | 72,200 |
| Wages (44) | 1,165,000 | 72,200 |
| Wages (45) | 1,165,000 | 72,200 |
| Wages (46) | 1,165,000 | 72,200 |
| Wages (47) | 1,165,000 | 72,200 |
| Wages (48) | 1,165,000 | 72,200 |
| Wages (49) | 1,165,000 | 72,200 |
| Wages (50) | 1,165,000 | 72,200 |
| Wages (51) | 1,165,000 | 72,200 |
| Wages (52) | 1,165,000 | 72,200 |
| Wages (53) | 1,165,000 | 72,200 |
| Wages (54) | 1,165,000 | 72,200 |
| Wages (55) | 1,165,000 | 72,200 |
| Wages (56) | 1,165,000 | 72,200 |
| Wages (57) | 1,165,000 | 72,200 |
| Wages (58) | 1,165,000 | 72,200 |
| Wages (59) | 1,165,000 | 72,200 |
| Wages (60) | 1,165,000 | 72,200 |
| Wages (61) | 1,165,000 | 72,200 |
| Wages (62) | 1,165,000 | 72,200 |
| Wages (63) | 1,165,000 | 72,200 |
| Wages (64) | 1,165,000 | 72,200 |
| Wages (65) | 1,165,000 | 72,200 |
| Wages (66) | 1,165,000 | 72,200 |
| Wages (67) | 1,165,000 | 72,200 |
| Wages (68) | 1,165,000 | 72,200 |
| Wages (69) | 1,165,000 | 72,200 |
| Wages (70) | 1,165,000 | 72,200 |
| Wages (71) | 1,165,000 | 72,200 |
| Wages (72) | 1,165,000 | 72,200 |
| Wages (73) | 1,165,000 | 72,200 |
| Wages (74) | 1,165,000 | 72,200 |
| Wages (75) | 1,165,000 | 72,200 |
| Wages (76) | 1,165,000 | 72,200 |
| Wages (77) | 1,165,000 | 72,200 |
| Wages (78) | 1,165,000 | 72,200 |
| Wages (79) | 1,165,000 | 72,200 |
| Wages (80) | 1,165,000 | 72,200 |
| Wages (81) | 1,165,000 | 72,200 |
| Wages (82) | 1,165,000 | 72,200 |
| Wages (83) | 1,165,000 | 72,200 |
| Wages (84) | 1,165,000 | 72,200 |
| Wages (85) | 1,165,000 | 72,200 |
| Wages (86) | 1,165,000 | 72,200 |
| Wages (87) | 1,165,000 | 72,200 |
| Wages (88) | 1,165,000 | 72,200 |
| Wages (89) | 1,165,000 | 72,200 |
| Wages (90) | 1,165,000 | 72,200 |
| Wages (91) | 1,165,000 | 72,200 |
| Wages (92) | 1,165,000 | 72,200 |
| Wages (93) | 1,165,000 | 72,200 |
| Wages (94) | 1,165,000 | 72,200 |
| Wages (95) | 1,165,000 | 72,200 |
| Wages (96) | 1,165,000 | 72,200 |
| Wages (97) | 1,165,000 | 72,200 |
| Wages (98) | 1,165,000 | 72,200 |
| Wages (99) | 1,165,000 | 72,200 |
| Wages (100) | 1,165,000 | 72,200 |

22

T. ROWE PRICE HEALTH SCIENCES FUND

| Allogene, Healthcare (1) | 1,216,992 | 14,311 |
| --- | --- | --- |
| Health Services, Service 15.0% | 1,248,000 | 14,311 |
| Emphysema, Series B, Acquisition Date: 1/21/22, Cost $8,808 (1) | 3,724,000 | 241,000 |
| Health, Series C, Acquisition Date: 10/26/21, Cost $4,414 (1) | 1,121,000 | 2,000 |
| Health and value in 3000s) | 1,011,000 | 2,000 |
| Emphysema, Series B, Acquisition Date: 1/17/22, Cost $2,621 (1)/2(2) | 1,008,000 | 842,000 |
| Health, Series C, Acquisition Date: 9/18/19, Cost $12,000 (1) | 1,008,000 | 842,000 |
| Health, Series C, Acquisition Date: 9/18/19, Cost $12,000 (1) | 3,974,000 | 148,000 |
| Health, Series C, Acquisition Date: 9/18/21, Cost $2,216 (1) | 1,101,000 | 2,000 |
| Health, Series C, Acquisition Date: 9/18/21, Cost $2,216 (1) | 1,008,000 | 842,000 |
| Health, Series C, Acquisition Date: 9/18/21, Cost $2,216 (1) | 1,101,000 | 2,000 |
| Health, Series C, Acquisition Date: 9/18/21, Cost $2,216 (1) | 1,008,000 | 842,000 |

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21, Cost $11,023 (1)

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21

Canada Medical, Series D, Acquisition Date: 12/30/21[{"box_2d": [35

T. ROWE PRICE HEALTH SCIENCES FUND

| Proprietary | 1,951,887 | 112,874 |
| --- | --- | --- |
| Cost of $5,501 (1)(2)(3) | 1,950,917 | 3,000 |
| Healthcare Services A(s) Acquisition Date: 2/28/22, | 1,952,888 | 2,000 |
| Health Care Services A(s) Acquisition Date: 5/21/20, Cost $5,505 (1)(2)(3) | 3,000,582 | 18,000 |
| Health Care Services A(s) Acquisition Date: 4/7/21, Cost $10,762 (1)(2)(3) | 500,382 | 1,250,000 |
| Health Care Services A(s) Acquisition Date: 2/28/22, | 512,163 | 12,017 |
| Health Care Services A(s) Acquisition Date: 7/28/21, Cost $32,757 (1)(2) | 2,605,184 | 2,500,000 |
| Health Care Services A(s) Acquisition Date: 5/18/21, Cost $13,294 (1) | 1,169,887 | 6,551 |
| Health Care Services A(s) Acquisition Date: 8/27/21, | 3,000,541 | 173,485 |
| Health Care Services A(s) Acquisition Date: 7/8/22, Cost $5,504 (1)(2)(3) | 1,826,085 | 3,525,000 |
| Health Care Services A(s) Acquisition Date: 8/21/22, | 2,855,807 | 679,000 |

24

T. ROWE PRICE HEALTH SCIENCES FUND

| Cost $7,048 (1)(2)(2) | 1,115,015 | 7,048 |
| --- | --- | --- |
| Paul H. S. Jones, Series C, Acquisition Date: 8/21/21, |  | 15,230,590 |
| Paul H. S. Jones, Series C, Acquisition Date: 8/27/22, Cost $4,414 (1)(2) | 861,217 | 17,704 |
| Paul H. S. Jones, Series C, Acquisition Date: 8/14/20, |  | 247,204 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/20, | 479,818 | 4,313 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/20, | 3,758,668 | 21,222 |
| Paul H. S. Jones, Series B, Acquisition Date: 8/21/21, | 1,452,941 | 714,960 |
| Paul H. S. Jones, Series B, Acquisition Date: 5/11/21, | 978,705 | 8,107 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/21, | 2,280,334 | 9,004 |
| Patricia S. S. Jones, Series C, Acquisition Date: 12/10/21, | 4,954 | 15,005 |
| Patricia S. S. Jones, Series B, Acquisition Date: 6/24/19, | 104,125 | 9,585 |
| Patricia S. S. Jones, Series B, Acquisition Date: 6/24/19, | 1,005,745 | 11,024 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/20, | 1,005,745 | 10,189 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/20, | 1,005,745 | 10,189 |
| Patricia S. S. Jones, Series C, Acquisition Date: 8/14/20, | 1,005,745 | 10,189 |

interest rate and maturity date are those of the original security.

25

T. ROWE PRICE HEALTH SCIENCES FUND

| Cost $6,219 (1)(2)(B) | 1,027,755 | 6,219 |
| --- | --- | --- |
| Briggs, 2010 Series C, Acquisition Date: 6/9/21 | 725,231 | 10,002 |
| Briggs, 2010 Series B, Acquisition Date: 2/2/22 | 426,855 | 25,923 |
| Briggs, 2010 Series D, Acquisition Date: 11/22/21 | 547,878 | 5,284 |
| Cost $5,261 (1)(2)(B) Hong Kong Dollar | 541,277 | 5,284 |
| Cost $5,261 (1)(2)(B) | 525,551 | 100,621 |
| Briggs, 2010 Series C, Acquisition Date: 11/15/19 | 387,032 | 94,785 |
| Briggs, 2010 Series D, Acquisition Date: 4/9/21-9/26/22 | 593,540 | 1,816 |
| Briggs, 2010 Series A, Acquisition Date: 4/9/21-9/26/22 |  |  |
| Briggs, 2010 Series A-S, Acquisition Date: 5/12/20, Cost $1,174 (1) | 2,370,150 | 18,552 |
| Briggs, 2010 Series B, Acquisition Date: 4/3/18 | 2,347,127 | 1,716 |
| Briggs, 2010 Series D, Acquisition Date: 4/3/18 | 2,347,127 | 1,716 |
| Briggs, 2010 Series A, Acquisition Date: 4/3/18 | 2,347,127 | 1,716 |
| Briggs, 2010 Series B, Acquisition Date: 3/11/20, Cost $8,533 (1) | 2,347,127 | 2,347 |
| Briggs, 2010 Series D, Acquisition Date: 4/3/20 | 2,347,127 | 2,347 |

26

T. ROWE PRICE HEALTH SCIENCES FUND

| Securities, or a company that is under common ownership or control. The following securities are not designated as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name and are not listed as a company's name | 2,000,000 | 2,000,000 |
| --- | --- | --- |
| 10.2% of Net Assets | Change in Net | 18,913 |
| Securities, Properties E, Acquisition Date: 8/23/18, | Net Realized | Unrealized |
| Supplementary Investment Schedule | 172,826 | 10,584 |

27

T. ROWE PRICE HEALTH SCIENCES FUND

December 31, 2022

| Chroma Medicine, Series A | Value | Purchase | Sales | Value |
| --- | --- | --- | --- | --- |
| Refinancing, Class A | $11,023 | Cost $4,200,000 | 6,648 | 12/31/22 |
| Refinancing, Class B | $11,023 | Cost $4,200,000 | 6,648 | 6,924 |
| Refinancing, Class C | $11,040 | Cost $4,200,000 | 11,712 | 13,674 |
| Refinancing, Class D | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class E | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class F | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class G | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class H | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class I | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class J | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class K | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class L | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class M | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class N | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class O | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class P | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class Q | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class R | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class S | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class T | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class U | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class V | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class W | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class X | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class Y | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class Z | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AA | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AB | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AC | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AD | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AE | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AF | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AG | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AH | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AI | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AJ | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AK | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AL | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AM | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AN | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AO | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AP | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AQ | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AR | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AS | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AT | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AU | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AV | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AW | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AX | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AY | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class AZ | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class BA | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class BB | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class BC | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class CD | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class CE | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class CF | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class CE | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |
| Refinancing, Class CE | $11,040 | Cost $4,200,000 | 11,712 | 11,040 |

28

T. ROWE PRICE HEALTH SCIENCES FUND

| STATEMENT OF ASSETS AND SECURITIES |  | in rights for certain restricted securities. Any costs |
| --- | --- | --- |
| Bonds, other than the listed assets and registration are generally borne by the issuer of the aggregate |  |  |
| Programs, Series, Cases, Restricted securities (excluding 3,488 holdings) at period end amount |  |  |
| Somal | 28,159 | 385 |
| Amount of Wages and other items of certain securities has been concealed to protect the fund while it |  |  |
| Somal Logic Class B completes a purchase of $1,385 | (5,703) | (29,858) |
| Somal Logic Form 4.0 (Companies) |  | Under |
| $20 |  | 12/31/2030 |
| Payable and non-payment of duties purchased |  | 17,387 |
| Trading and non-payment of duties purchased | 11,332 | - |
| Investment management fees payable |  | 8,914 |
| Due (Net of foreign taxes of $1,385) |  | $115,915796 |
| Payable to directors |  | 910 |
| Other |  | 115,914575 |
| Expenses |  |  |

The accompanying notes are an integral part of these financial statements.

29

T. ROWE PRICE HEALTH SCIENCES FUND

# STATEMENT OF OPERATIONS

| Revenue Fund, 4.30% | 12,084 | 0 | 0 | 158,976 |
| --- | --- | --- | --- | --- |
| Total |  |  |  | $223,708^ |
| Total liabilities |  |  |  | 68,212 |
| # Capital gain management from underlying Price funds represented $0 of the net realized value |  |  |  | 101,981 |
| (In Shareholder provision) |  |  |  | 1,000 |
| + Income from the completed cash in-products income and go of $0.00 income. |  |  |  | 16,172,991 |
| Realized and Unrealized Gain / Loss |  |  |  | 15,772 |
| Purchase and sale information not shown for cash management funds |  |  |  | 18,353 |
| Net realized value |  |  |  |  |
| Perspective net shareholder reports |  |  |  | $7,690,227 |
| Taxes |  |  |  | (1,590,227) |
| Passport and applicable to 179,996,928 shares of $0.0001 |  |  |  | (550) |
| Foreign currency transactions |  |  |  | 90 |
| par value of capital stock outstanding; 1,000,000,000 shares |  |  |  | (14,587) |
| authorized and accounting |  |  |  | 8,492,764 |

The accompanying notes are an integral part of these financial statements.

30

T. ROWE PRICE HEALTH SCIENCES FUND

# STATEMENT OF OPERATIONS

In the date indicated, issuer was held but not considered an affiliated company.[{"box_2d": [68, 135, 609, 240], "label": "table", "caption": "

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |
| Increase (Decrease) in Net Assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |
| Net assets |  | (2,384,261) |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |
| Net assets | 12/31/22 | $16,172,391 |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td>12/31/22</td><td>$16,172,391</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td>12/31/22</td><td>$16,172,391</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td>12/31/22</td><td>$16,172,391</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit | Year Ended | 292 |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td>12/31/22</td><td>$16,172,391</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table>

| Legal and audit |  | (2,384,261) |
| --- | --- | --- |

<tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></tabletabletable><thead><tr><th>Legal and audit</th><th></th><th>(2,384,261)</th></tr></table><tr><td>Net assets</td><td></td><td>(2,384,261)</td></tr></table[{"box_2d": [35, 657, 400, 670], "label": "text", "[Table 1: 2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015</td><td>2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015</td><td>2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-2015-</td></tr></table>"}][{"box_2d": [35, 657, 400, 670], "label": "text", "caption": "The accompanying notes are an integral

T. ROWE PRICE HEALTH SCIENCES FUND

# STATEMENT OF CHANGES IN NET ASSETS

($000s)

| ($5,937,842,426 / 66,044,049 shares outstanding) | Year | $ | 89.91 |
| --- | --- | --- | --- |
| Distributions to shareholders | Ended |  |  |
|  | 12/31/22 |  | 12/31/21 |
| Net Assets Class | (179,171) |  | (1,202,597) |
| Increase/(decrease) during period | (1,035,681) |  | (1,075,654) |
| Decrease of period assets from distributions | 1,037,842 |  | (1,104,168) |
| End of period | $16,172,991 |  | $19,508,842 |

Capital share transactions

*Share information (000s)

32

T. ROWE PRICE HEALTH SCIENCES FUND

# PROVISIONS OF GUARANTEE IN THE ACTIVE financial statements.

($000s)

Shares sold
Shares sold
Investor Class 1,236,168 1,935,820
Companion of 1940 (the 1940 Act) as a diversified, open-ended management management
Class 4,332,268 667,935
Companion of the fund seeks long-term capital appreciation. The fund has two classes of
Distributions reinvested
Distributions reinvested
Shares sold
Investor Class 1,395 1,145,673 Class
(1 Class) 1,395 1,145
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the 1940s
Shares in the

The accompanying notes are an integral part of these financial statements.

33

T. ROWE PRICE HEALTH SCIENCES FUND

# **NOTICE TO FINANCIAL STATEMENTS**

T. Rowe Price Health Sciences Fund, Inc. (the fund) is registered under the Investment (I Class) (decrease) in net assets from capital share (567,212) (287,745) in the financial statements of the fund. The fund may also be declared and paid by the investment company and other certain accounts. As a result of this election in the I Class fund annually, certain assets transferred from the Investor Class to the I Class. This transfer of assets from the Investor Class to I Class is reflected in the Statement of Changes in Net Assets within the Capital Share transactions in States under any and all previous agreements. Each using the mean of the two hundred and one-half percent of such currencies against separate voting rights on matters that relate to both classes; and, in all other respects, the same rights and obligations as the other class.

34

T. ROWE PRICE HEALTH SCIENCES FUND

in net unrealized gain/loss from securities. Distributions to shareholders are recorded U.S. dollars as provided by an outside pricing service. Purchases and sales of securities, income and expenses are translated into U.S. dollars at the prevailing exchange rate on the respective date of such transaction. The effect of changes in foreign currency reported at fair value, which GAAP defines as the price that would be received to sell an exchange rates on realized and unrealized security gains and losses is not influenced. Asset or paid to transfer a liability in an orderly transaction between market participants from the price attributable to the business or financial indices.

**NOTE 3. SIGNIFICANT ACCOUNTING POLICIES**

T. Rowe Price Associates, Inc. as the fund's valuation, desiraces (Valuation, Designated and Issued) and the financial statements of the Company and follows accounting and subject to oversight by the Board, the Valuation, Desiraces, performs the following reporting guidance in the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 (ASC 946). The accompanying financial statements

35

T. ROWE PRICE HEALTH SCIENCES FUND

# **NOTE 2 - VALUATION**

functions in performing fair value determinations: assesses and manages valuation common to all classes, investment income, and realized and unrealized gains and losses respectively. The following are applied for value determinations, over the fair value (unfunded) and are allocated to the classes based upon the relative daily net assets of each class. The values are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of the classes and are based on the average value of

Capital in the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States

**Investment Transactions, Investment Income, and Distributions** Investment

36

T. ROWE PRICE HEALTH SCIENCES FUND

**Valuation Techniques** Equity securities, including exchange-traded funds, listed or normal close of the NYSE if trading on the NYSE is restricted, if the NYSE closes earlier, in order to meet the value of the value of securities. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of the NYSE. The NYSE is not a member of

37

T. ROWE PRICE HEALTH SCIENCES FUND

flows; yield to maturity; or some combination. Fair value determinations are reviewed

based on the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value

| Investments in Value | Valuation | Significant Unobservable | Value or Range of | Weighted Average of | Impact to Valuation from an Increase |
| --- | --- | --- | --- | --- | --- |

38

T. ROWE PRICE HEALTH SCIENCES FUND

a wide variety of factors and inputs, both observable and unobservable, in determining

| Investments in | Value | Valuation | Significant Unobservable | Value or Range of | Weighted Average of | Impact to Valuation from an Increase |
| --- | --- | --- | --- | --- | --- | --- |
| observable inputs | not to minimize the impact of unobservable inputs. | unobservable inputs. | unobservable inputs. | unobservable inputs. | When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the Investments for which market quotations are not readily available or deemed unreliable following its preconditions. | the level within the Investments for which market quotations are not readily available or deemed unreliable following its preconditions. |

The financial instrument is a measure of unobservable inputs. When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the Investments for which market quotations are not readily available or deemed unreliable following its preconditions.

39

T. ROWE PRICE HEALTH SCIENCES FUND

Securities (000s) Technique(s)+ Input(s) Input(s) Input(s)* in Input**

are valued at fair value as determined in good performance. The Valuation Designee. The
of the financial instrument, input levels are determined by an indication of the fair
Valuation Designee has adopted methodology and determining the fair value of
the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value

40

T. ROWE PRICE HEALTH SCIENCES FUND

participants transaction information can be obtained from the United States Department of Health and Human Services. No quantitative unobservable inputs significantly to the valuation technique were created by the representative of fair value. However, the valuation technique also can be used to determine the impact of the value on the value of the value. For federal income tax, the value required since the fund intends to be used to calculate the valuation methods, such as market-based valuation principles, and the amount of premium. The value of the value of the value is calculated as a result of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value

NOTE: OTHER INVESTMENT TRANSACTIONS - 30.5% (84,760) 714,986

Distributions determined in accordance with the income tax regulations may differ from multiple. Consistent with its investment objective, the fund estimates in the following practices, the amount of character from the fund to the fund's share of the fund is increased to manage exposure to certain factors. The investment is not to be used to determine the impact of the value on the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value of the value

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

41

T. ROWE PRICE HEALTH SCIENCES FUND

# **NOTE 4 - FEDERAL INCOME TAXES**

In accordance with the GAAP, the following activities of the United States are described in the following table. The fund, files U.S. federal, state, and local tax returns, as required. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are the State and State tax. The funds, tax, and other taxes are

Private Investments issued by Special Purpose Acquisition Companies

42

T. ROWE PRICE HEALTH SCIENCES FUND

At December 31, 2022, the tax-basis components of accumulated net earnings (loss)

Capital payments and other financial instruments are not to be used for the current financial statements. Total attributable earnings (loss) is 7,880,227. The fund is managed by T. Rowe Price Associates, Inc. (Price Associates), a wholly owned subsidiary of T. Rowe Price Group, Inc. (Price Group) Inc. investment management agreement between the fund and Price Associates provides for an annual investment management fee that consists of an individual fund fee and a group fee; these differences shall reverse in a subsequent letter to the Company. The Company is not a member of the Company. The Company is not a member of the Company. The Company is not a member of the Company.

43

T. ROWE PRICE HEALTH SCIENCES FUND

# **NOTE 6 - RELATED PARTY TRANSACTIONS**

The following table shows the results of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research and development of the research

**NOTE 5 - FOREIGN TAXES** at least through April 30, 2023, to waive a portion of its other purchases and sales of products, securities, and other services and two

44

T. ROWE PRICE HEALTH SCIENCES FUND

The fund may participate in securities purchase and sale transactions with other funds

45

T. ROWE PRICE HEALTH SCIENCES FUND

accounts managed by Price Associates or its affiliates and are not available for direct
Normalized Intervention for T. Rowe Price Services, Inc. and $605,000 for T. Rowe Price
Association. The Association of T. Rowe Price Services, Inc. and $605,000 for T. Rowe Price
Association are not affiliated with the Association of T. Rowe Price
Association. The Association of T. Rowe Price Services, Inc. and $605,000 for T. Rowe Price
Association are not affiliated with the Association of T. Rowe Price
Association. The Association of T. Rowe Price Services, Inc. and $605,000 for T. Rowe Price
Association are not affiliated with the Association of T. Rowe Price
Association. The Association of T. Rowe Price Services, Inc. and $605,000 for T. Rowe Price
Association are not affiliated with the Association of T. Rowe Price

46

T. ROWE PRICE HEALTH SCIENCES FUND

These are recent examples of global events which may have a negative impact on the Price Associates has voluntarily agreed to reimburse the fund from its own resources on the basis of the funds in accordance with the Company's shareholding law. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment.

To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, the fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment. The fund is a monthly basis for the cost of investment research embedded in the cost of the fund's investment.

47

T. ROWE PRICE HEALTH SCIENCES FUND

# REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

portfolio of investments, of T. Rowe Price Health Sciences Fund, Inc. (the "Fund") as of

(CONTINUED) 1st, 2022 the related statement of operations for the year ended December

2022. The statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations in the years ended December 31, 2022, the statement of operations

48

T. ROWE PRICE HEALTH SCIENCES FUND

# REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

By its compliance with the provisions of the General Regulations of the United States, the Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete. The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

The report is based on the information contained in this report. The Bureau of the Census (BCC) has determined that the information contained in this report is accurate and complete.

49

T. ROWE PRICE HEALTH SCIENCES FUND

# TAX INFORMATION (UNAUDITED) FOR THE TAX YEAR ENDED 12/31/22

RECORDS
$281,826,000 from long-term capital gains subject to a long-term capital gains tax rate
(see above) and public accounting and insurance with the public company (Accounting
and other) (PCAOB) and are required to be independent with
the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB) and the public company (PCAOB).

50

T. ROWE PRICE HEALTH SCIENCES FUND

# **INFORMATION ON PROXY VOTING POLICIES, PROCEDURES, AND**

reasonable assurance about whether the financial statements are free of material
corporate websites. To access it, please visit the following Web page:
misstatement, whether due to error or fraud.

In accordance with Rule 2 of 4 (Legality Rule) under the Investment Company Act
of 1940, as amended, the fund has established a liquidity risk management program
(Liquidity Program) reasonably designed to assess and manage the fund's liquidity risk,
which generally represents the risk that the fund would not be able to meet redemption
requests without significant dilution of remaining investors' interests in the fund. The
Each fund's most recent annual proxy voting record is available on our website and
through the SEC's website. To access it through T. Rowe Price, visit the website location
Price Associates, Inc. (Adviser), as the administrator of the Liquidity Program. As

51

T. ROWE PRICE HEALTH SCIENCES FUND

# **LIQUIDITY RISK MANAGEMENT PROGRAM**

shown above, and scroll down to the section near the bottom of the page that says
surrounding. The Adviser is responsible for overseeing the day-to-day operations of the
United States, including management and portfolio management, and the
Liquidity Program, and among other things, is responsible for assessing, managing,
during the period, cash flow projections, and other relevant data for the period of April 1,
and reviewing with the Board at least annually the liquidity risk of each T. Rowe Price
Health Sciences Fund. It is also responsible for the methodology for classifying
the T. Rowe Price Health Sciences Fund and the Liquidity Program to a Liquidity Risk
and a fund's investments (including any derivative transactions) into one of four liquidity
Economies (LRC) which is a more favorable consumer component of personnel from
the United States, as well as the percentage of a fund's investments assigned to each category.
In some departments within the Adviser,
It also is responsible for the methodology for establishing a fund's investment in the
LRC
and the Liquidity Program's principal fund's investment in the LRC

52

T. ROWE PRICE HEALTH SCIENCES FUND

For the fund and other T. Rowe Price funds, the annual assessment incorporated a report electronically on the SEC's website (see text) in addition to the T. Rowe Price funds. The fund was based on the annual assessment of the SEC's website (see text) in addition to the T. Rowe Price funds. Your fund is based on the annual assessment of the SEC's website (see text) in addition to the T. Rowe Price funds. Your fund is based on the annual assessment of the SEC's website (see text) in addition to the T. Rowe Price funds. Your fund is based on the annual assessment of the SEC's website (see text) in addition to the T. Rowe Price funds. Your fund is based on the annual assessment of the SEC's website (see text) in addition to the T. Rowe Price funds.

53

T. ROWE PRICE HEALTH SCIENCES FUND

# **ABOUT THE FUND'S DIRECTORS AND OFFICERS**

21202. This is a series of 4 monthly interviews of four key organizations based on the results of the directors investment activity to be held by the top 10 of the Fund's Directors. The Fund's investment activity is a series of 4 monthly interviews of four key organizations based on the results of the directors investment activity to be held by the top 10 of the Fund's Directors. The Fund's investment activity is a series of 4 monthly interviews of four key organizations based on the results of the directors investment activity to be held by the top 10 of the Fund's Directors. The Fund's investment activity is a series of 4 monthly interviews of four key organizations based on the results of the directors investment activity to be held by the top 10 of the Fund's Directors.

**INDEPENDENT DIRECTORS**
(Number of T. Rowe Price, Principal Occupation(s), and Directorate(s), of Public Companies, and Non-Profit Organs)
Nationally Owned and/or Subscribed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and
(Year of Birth) Addressed the operation of the Liquidity Program and assessed its adequacy and

54

T. ROWE PRICE HEALTH SCIENCES FUND

# **INDEPENDENT DIRECTORS (CONTINUED)**

Member of T. Rowe Price Principal Occupation(s) and Directorships of Public Companies and Portfolios (Overseas) (Other Investment Companies During the Past Five Years) is a member of the National Association for the Advancement of Public Companies (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA)

Member of T. Rowe Price Principal Occupation(s) and Directorships of Public Companies and Portfolios (Overseas) (Other Investment Companies During the Past Five Years) is a member of the National Association for the Advancement of Public Companies (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA)

Member of T. Rowe Price Principal Occupation(s) and Directorships of Public Companies and Portfolios (Overseas) (Other Investment Companies During the Past Five Years) is a member of the National Association for the Advancement of Public Companies (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA)

Member of T. Rowe Price Principal Occupation(s) and Directorships of Public Companies and Portfolios (Overseas) (Other Investment Companies During the Past Five Years) is a member of the National Association for the Advancement of Public Companies (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA) (NAPA)

55

T. ROWE PRICE HEALTH SCIENCES FUND

# **INTERESTED DIRECTORS (CONTINUED)**

2000-2011, cash and cash equivalents, as well as available borrowing arrangements.
Department: The South Hopkins University (2009 to present); Director, Projective April 27, 2022, Mr. Daniels resigned from his role as an independent director of the Price
Lyndhurst Holdings (2015 to present); Director, Bluegibbo Pharma, Inc.
Fund.
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100

56

T. ROWE PRICE HEALTH SCIENCES FUND

# OFFICERS (CONTINUED)

| Year (Years) | Results, a hotel and leisure company: Member, Investment Company |
| --- | --- |
| Number of T. Rowe Price | Principal Occupation: Director, Home Office, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| Name (W. O'Neil, D. R. H.) | Other Investment Companies: Director, Home Office, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| Position Held With Health Sciences Fund | Principal Accountant(s): Director, Home Office, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| David Oestreicher | Director, Home Office, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| George W. O'Neil (1996) | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home |
| W. O'Neil, D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| W. O'Neil, D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| W. O'Neil, D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| W. O'Neil, D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |
| W. O'Neil, D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R. H., D. R | Member, Services, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care, Home Care |

57

Name (Year of Birth)
Position Held With Health Sciences Fund Principal Occupation(s)

T. ROWE PRICE HEALTH SCIENCES FUND

# **OFFICERS (CONTINUED)**

Armando (Dino) Capasso (1974) Chief Compliance Officer
Jeffrey Holford, Ph.D., ACA (1973) Vice President
Robert D. Jones (1983) Vice President
Vice Japan (Price Signatory); General Manager; Chief Executive Officer; Chief of the Board; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer; President; Chief Executive Officer

![img-0.jpeg](img-0.jpeg)

58

Name (Year of Birth)
Position Held With Health Sciences Fund Principal Occupation(s)

Item 1. (b) Notice pursuant to Rule 30e-3.

Not applicable.

# Item 2. Code of Ethics.

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, and the following similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics. The following period of the registrant is: 1. January 2017 (the first time of the year), 2. February 2017 (the second time of the year), 3. March 2017 (the third time of the year), 4. April 2017 (the fourth time of the year), 5. May 2017 (the fifth time of the year), 6. June 2017 (the sixth time of the year), 7. July 2017 (the seventh time of the year), 8. August 2017 (the eighth time of the year), 9. September 2017 (the 10th time of the year), 10. October 2017 (the 11st time of the year), 11. November 2017 (the 12nd time of the year), 12. December 2017 (the 13rd time of the year), 13. January 2018 (the 14th time of the year), 14. February 2018 (the 15th time of the year), 15. March 2018 (the 16th time of the year), 16. April 2018 (the 17th time of the year), 17. May 2018 (the 18th time of the year), 18. June 2018 (the 19th time of the year), 19. September 2018 (the 20th time of the year), 20. October 2018 (the 21st time of the year), 21. November 2018 (the 22nd time of the year), 22. December 2018 (the 23rd time of the year), 23. January 2019 (the 24th time of the year), 24. February 2019 (the 25th time of the year), 25. March 2019 (the 26th time of the year), 26. April 2019 (the 27th time of the year), 27. May 2019 (the 28th time of the year), 28. June 2019 (the 29th time of the year), 29. September 2019 (the 30th time of the year), 30. October 2019 (the 31st time of the year), 31. November 2019 (the 32nd time of the year), 32. December 2019 (the 33rd time of the year), 33. January 2020 (the 34th time of the year), 34. February 2020 (the 35th time of the year), 35. March 2020 (the 36th time of the year), 36. April 2020 (the 37th time of the year), 37. May 2020 (the 38th time of the year), 38. June 2020 (the 39th time of the year), 39. September 2020 (the 40th time of the year), 40. October 2020 (the 41st time of the year), 41. November 2020 (the 42nd time of the year), 42. December 2020 (the 43rd time of the year), 43. January 2021 (the 44th time of the year), 44. February 2021 (the 45th time of the year), 45. March 2021 (the 46th time of the year), 46. April 2021 (the 47th time of the year), 47. May 2021 (the 48th time of the year), 48. June 2021 (the 49th time of the year), 49. September 2021 (the 50th time of the year), 50. October 2021 (the 51st time of the year), 51. November 2021 (the 52nd time of the year), 52. December 2021 (the 53rd time of the year), 53. January 2022 (the 54th time of the year), 54. February 2022 (the 55th time of the year), 55. March 2022 (the 56th time of the year), 56. April 2022 (the 57th time of the year), 57. May 2022 (the 58th time of the year), 58. June 2022 (the 59th time of the year), 59. September 2022 (the 60th time of the year), 60. October 2022 (the 61st time of the year), 61. November 2022 (the 62nd time of the year), 62. December 2022 (the 63rd time of the year), 63. January 2023 (the 64th time of the year), 64. February 2023 (the 65th time of the year), 65. March 2023 (the 66th time of the year), 66. April 2023 (the 67th time of the year), 67. May 2023 (the 68th time of the year), 68. June 2023 (the 69th time of the year), 69. September 2023 (the 70th time of the year), 70. October 2023 (the 71st time of the year), 71. November 2023 (the 72nd time of the year), 72. December 2023 (the 73rd time of the year), 73. January 2024 (the 74th time of the year), 74. February 2024 (the 75th time of the year), 75. March 2024 (the 76th time of the year), 76. April 2024 (the 77th time of the year), 77. May 2024 (the 78th time of the year), 78. June 2024 (the 79th time of the year), 79. September 2024 (the 80th time of the year), 80. October 2024 (the 81st time of the year), 81. November 2024 (the 82nd time of the year), 82. December 2024 (the 83rd time of the year), 83. January 2025 (the 84th time of the year), 84. February 2025 (the 85th time of the year), 85. March 2025 (the 86th time of the year), 86. April 2025 (the 87th time of the year), 87. May 2025 (the 88th time of the year), 88. June 2025 (the 89th time of the year), 89. September 2025 (the 90th time of the year), 90. October 2025 (the 91st time of the year), 91. November 2025 (the 92nd time of the year), 92. December 2025 (the 93rd time of the year), 93. January 2026 (the 94th time of the year), 94. February 2026 (the 95th time of the year), 95. March 2026 (the 96th time of the year), 96. April 2026 (the 97th time of the year), 97. May 2026 (the 98th time of the year), 98. June 2026 (the 99th time of the year), 99. September 2026 (the 100th time of the year).

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, and the following similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics. The following period of the registrant is: 1. January 2017 (the first time of the year), 2. February 2017 (the second time of the year), 3. March 2017 (the third time of the year), 4. April 2017 (the fourth time of the year), 5. May 2017 (the fifth time of the year), 6. June 2017 (the sixth time of the year), 7. July 2017 (the seventh time of the year), 8. August 2017 (the eighth time of the year), 9. September 2017 (the 10th time of the year), 10. October 2017 (the 11st time of the year), 11. November 2017 (the 12nd time of the year), 12. December 2017 (the 13rd time of the year), 13. January 2018 (the 14th time of the year), 15. February 2018 (the 16th time of the year), 16. March 2018 (the 17th time of the year), 17. May 2018 (the 18th time of the year), 18. June 2018 (the 19th time of the year), 19. September 2018 (the 20th time of the year), 20. October 2018 (the 21st time of the year), 21. November 2018 (the 22nd time of the year), 22. December 2018 (the 23rd time of the year), 23. January 2019 (the 24th time of the year), 24. February 2019 (the 25th time of the year), 25. March 2019 (the 26th time of the year), 26. April 2019 (the 27th time of the year), 27. May 2019 (the 28th time of the year), 28. June 2019 (the 29th time of the year), 29. September 2019 (the 30th time of the year).

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, and the following similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics. The following period of the registrant is: 1. January 2017 (the first time of the year), 2. February 2017 (the second time of the year), 3. March 2017 (the third time of the year), 4. April 2017 (the fourth time of the year), 5. May 2017 (the fifth time of the year), 6. June 2017 (the sixth time of the year), 7. July 2017 (the seventh time of the year), 8. August 2017 (the eighth time of the year), 9. September 2017 (the 10th time of the year), 10. October 2017 (the 11st time of the year), 11. November 2017 (the 12nd time of the year), 12. December 2017 (the 13rd time of the year), 13. January 2018 (the 14th time of the year), 15. February 2018 (the 16th time of the year), 16. March 2018 (the 17th time of the year), 17. May 2018 (the 18th time of the year), 18. June 2018 (the 19th time of the year), 19. September 2018 (the 20th time of the year).

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, and the following similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics. The following period of the registrant is: 1. January 2017 (the first time of the year), 2. February 2017 (the second time of the year), 3. March 2017 (the third time of the year), 4. April 2017 (the fourth time of the year), 5. May 2017 (the fifth time of the year), 6. June 2017 (the sixth time of the year), 7. July 2017 (the seventh time of the year), 8. August 2017 (the eighth time of the year), 9. September 2017 (the 10th time of the year).

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, and the following similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics. The following period of the registrant is: 1. January 2017 (the first time of the year), 2. February 2017 (the second time of the year), 3. March 2017 (the third time of the year), 4. April 2017 (the fourth time of the year), 5. May 2017 (the fifth time of the year), 6. June 2017 (the sixth time of the year), 7. July 2017 (the seventh time of the year), 8. August 2017 (the eighth time of the year), 9. September 2017 (the 10th time of the year).

|  | 2022 | 2021 |
| --- | --- | --- |
| Audit Fees | $41,909 | $40,759 |
| Audit-Related Fees | - | - |
| Tax Fees | - | 5,742 |
| All Other Fees | - | - |

Audit fees include amounts related to the audit of the registrant's annual financial statements and services normally provided by the accountant in connection with statutory and regulatory filings. Audit-related fees include amounts reasonably related to the performance of the audit of the registrant's financial statements and specifically include the issuance of a report on internal controls and, if applicable, agreed-upon procedures related to fund acquisitions. Tax fees include amounts related to services for tax compliance, tax planning, and tax advice. The nature of these services specifically includes the review of distribution calculations and the preparation of Federal, state, and excise tax returns. All other fees include the registrant's pro-rata share of amounts for agreed-upon procedures in conjunction with service contract approvals by the registrant's Board of Directors/Trustees.

(e)(1) The registrant's audit committee has adopted a policy whereby audit and non-audit services performed by the registrant's principal accountant for the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant require pre-approval in advance at regularly scheduled audit committee meetings. If such a service is required between regularly scheduled audit committee meetings, pre-approval may be authorized by one audit committee member with ratification at the next scheduled audit committee meeting. Waiver of pre-approval for audit or non-audit services requiring fees of a de minimis amount is not permitted.

(2) No services included in (b) - (d) above were approved pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

T. Rowe Price Investment Services, Inc. | 100 East Pratt Street | Baltimore, MD 21202-1009

(f) Less than 50 percent of the hours expended on the principal accountant's engagement to audit the registrant's financial statements for the most recent fiscal year were attributed to work performed by persons other than the principal accountant's full-time, permanent employees.

(g) The aggregate fees billed for the most recent fiscal year and the preceding fiscal year by the registrant's principal accountant for non-audit services rendered to the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant were $2,037,000 and $3,732,000, respectively.

(h) All non-audit services rendered in (g) above were pre-approved by the registrant's audit committee. Accordingly, these services were considered by the registrant's audit committee in maintaining the principal accountant's independence.

Unless otherwise noted, officers have been employed by T. Rowe Price or Price International for at least 5 years.

Item 5. Identification of Listed Registrants

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

Taymou, B. Jannar, CFO (1976)

(b) The registrant's principal executive officer and principal financial officer are aware of no change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.**

Unless otherwise noted, officers have been employees of T. Rowe Price or Price International for at least

5 years.

**Item 13. Exhibits.**

(a)(1) The registrant's code of ethics pursuant to Item 9 of Form N-2-98 is attached. (CIGMA/UTMAS)
(2) See the information on the registrant's principal executive officer and principal financial officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(a) under the Investment Companies Act of 1940, are attached.
(3) Written information to report these securities issued by closed-end companies: not applicable.
(b) A report of the registrant's principal executive officer and principal financial officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(b) under the Investment Companies Act of 1940 is attached.

Unless otherwise noted, officers have been employees of T. Rowe Price or Price International for at least 5 years.

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

T. Rowe Price Health Sciences Fund, Inc.

By /s/ David Oestreicher
David Oestreicher
Principal Executive Officer

Date February 16, 2023
*Call 1-800-225-5132 to request a prospectus or summary prospectus; each includes investment objectives, risks, fees, expenses, and other information that you should read and consider carefully before investing.*

All mutual funds are subject to market risk including available risk information. Investing internationally involves issuers and investment partners and includes uncertainty and currency fluctuation.

By T. Rowe Price Health Sciences Fund, Inc.
David Oestreicher
Principal Executive Officer

Date February 16, 2023

By /s/ Alan S. Dupski
Alan S. Dupski
Principal Financial Officer

Date February 16, 2023

T. Rowe Price Advisory Services, Inc., a registered investment adviser under the Investment Advisers Act of 1940. Brokerage services are provided by T. Rowe Price Investment Services, Inc., member FINRA/SIPC. Brokerage accounts are carried by Pershing LLC, a BNY Mellon Company, member NYSE/FINRA/SIPC. T. Rowe Price Advisory Services, Inc., and T. Rowe Price Investment Services, Inc., are affiliated companies.

$^{2}$ Brokerage services are provided by T. Rowe Price Investment Services, Inc., member FINRA/SIPC. Brokerage accounts are carried by Pershing LLC, a BNY Mellon Company, member NYSE/FINRA/SIPC.

202302-2582632  
F114-0502/23

## Ex-99.Cert

**Item 13. (a)(2)** 

**<u>CERTIFICATIONS</u>**

I, David Oestreicher, certify that:

1. I have reviewed this report on Form N-CSR of T. Rowe Price Health
Sciences Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the
periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 16, 2023 | /s/ David Oestreicher |
|  | David Oestreicher |
|  | Principal Executive Officer |

---

------

**<u>CERTIFICATIONS</u>**

I, Alan S. Dupski, certify that:

1. I have reviewed this report on Form N-CSR of T. Rowe Price Health
Sciences Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the
periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 16, 2023 | /s/ Alan S. Dupski |
|  | Alan S. Dupski |
|  | Principal Financial Officer |

---

## Exhibit 99.906

**Item 13. (b)** 

**CERTIFICATION UNDER SECTION 906 OF SARBANES-OXLEY ACT OF 2002** 

Name of Issuer: T. Rowe Price Health Sciences Fund

In connection with the Report on Form N-CSR for the above named Issuer, the undersigned hereby certifies, to the best of his knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Issuer.

---

| | |
|:---|:---|
| Date: February 16, 2023 | /s/ David Oestreicher |
|  | David Oestreicher |
|  | Principal Executive Officer |
| Date: February 16, 2023 | /s/ Alan S. Dupski |
|  | Alan S. Dupski |
|  | Principal Financial Officer |

---

## Ex-99.Code

**CODE OF ETHICS FOR PRINCIPAL EXECUTIVE AND SENIOR FINANCIAL** 

**OFFICERS OF THE T. ROWE PRICE MUTUAL FUNDS AND EXCHANGE-** 

**TRADED FUNDS** 

**UNDER THE SARBANES-OXLEY ACT OF 2002** 

**I. General Statement.** This Code of Ethics for the T. Rowe Price Mutual Funds and Exchange-Traded Funds (the "Price ETFs" and, together with the Mutual Funds, the **"Price Funds")** has been designed to bring the Price Funds into compliance with the applicable requirements of the Sarbanes-Oxley Act of 2002 (the **"Act")** and rules promulgated by the Securities and Exchange Commission thereunder ("Regulations"). This Price Funds' Code of Ethics (the **"S-O Code")** applies solely to the Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer or Controller of, or persons performing similar functions for, a Price Fund (whether such persons are employed by a Price Fund or third party) **("Covered Officers").** The **"Price Funds"** shall include each mutual fund and ETF that is managed, sponsored and distributed by affiliates of T. Rowe Price Group, Inc. **("Group").** The investment managers to the Price Funds will be referred to as the **"Price Fund Advisers."** A list of Covered Officers is attached as **Exhibit A.**

The Price Fund Advisers have, along with their parent, T. Rowe Price Group, Inc. **("Group")** also maintained a comprehensive Code of Ethics and Conduct (the **"Group Code")** since 1972, which applies to all officers, directors and employees of the Price Funds, Group and its affiliates.

As mandated by the Act, Group has adopted a Code (the **"Group S-O Code"),** similar to the Price Funds S-O Code, which applies solely to its principal executive and senior financial officers. The Group S-O Code and the Price Funds S-O Code will be referred to collectively as the **"S-O Codes".**

The Price Funds S-O Code has been adopted by the Price Funds in accordance with the Act and Regulations thereunder and will be administered in conformity with the disclosure requirements of Item 2 of Form N-CSR. The S-O Codes are attachments to the Group Code. In many respects the S-O Codes are supplementary to the Group Code, but the Group Code is administered separately from the S-O Codes, as the S-O Codes are from each other.

**II. Purpose of the Price Funds S-O Code.** The purpose of the Price Funds S-O Code, as mandated by the Act and the Regulations, is to establish standards that are reasonably designed to deter wrongdoing and to promote:

**Ethical Conduct.** Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.

**Disclosure.** Full, fair, accurate, timely and understandable disclosure in reports and documents that the Price Funds file with, or submit to, the SEC and in other public communications made by the Price Funds.

**Compliance.** Compliance with applicable governmental laws, rules and regulations.

**Reporting of Violations.** The prompt internal reporting of violations of the Price Funds S-O Code to an appropriate person or persons identified in the Price Funds S-O Code.

**Accountability.** Accountability for adherence to the Price Funds S-O Code.

------

**III. Covered Officers Should Handle Ethically Actual and Apparent Conflicts of Interest.** 

**Overview.** Each Covered Officer owes a duty to the Price Funds to adhere to a high standard of honesty and business ethics and should be sensitive to situations that may give rise to actual as well as apparent conflicts of interest.

A "conflict of interest" occurs when a Covered Officer's private interest interferes with the interests of, or his or her service to, the Price Funds. For example, a conflict of interest would arise if a Covered Officer, or a member of his or her family, receives improper personal benefits as a result of his or her position with a Price Fund.

Certain conflicts of interest covered by the Price Funds S-O Code arise out of the relationships between Covered Officers and the Price Funds and may already be subject to provisions regulating conflicts of interest in the Investment Company Act of 1940 **("Investment Company Act"),** the Investment Advisers Act of 1940 **("Investment Advisers Act")** and the Group Code. For example, Covered Officers may not individually engage in certain transactions (such as the purchase or sale of securities or other property) with a Price Fund because of their status as "affiliated persons" of a Price Fund. The compliance programs and procedures of the Price Funds and Price Fund Advisers are designed to prevent, or identify and correct, violations of these provisions.

Although typically not presenting an opportunity for improper personal benefit, conflicts arise from, or as a result of, the contractual relationship between a Price Fund and its Price Fund Adviser (and its affiliates) of which the Covered Officers may also be officers or employees. As a result, the Price Funds S-O Code recognizes that the Covered Officers will, in the normal course of their duties (whether formally for the Price Funds or for the Price Fund Advisers, or for both), be involved in establishing policies and implementing decisions which will have different effects on these entities. The participation of the Covered Officers in such activities is inherent in the contractual relationship between each Price Fund and its respective Price Fund Adviser. Such participation is also consistent with the performance by the Covered Officers of their duties as officers of the Price Funds and, if consistent with the provisions of the Investment Company Act and the Investment Advisers Act, it will be deemed to have been handled ethically.

Other conflicts of interest are covered by the Price Funds and Price ETFs S-O Code, even if these conflicts of interest are not addressed by or subject to provisions in the Investment Company Act and the Investment Advisers Act.

Whenever a Covered Officer is confronted with a conflict of interest situation where he or she is uncertain as to the appropriate action to be taken, he or she should discuss the matter with the Chairperson of Group's Ethics Committee or another member of the Committee.

**Handling of Specific Types of Conflicts.** Each Covered Officer (and close family members) must not:

**Entertainment.** Accept entertainment from any company with which any Price Fund or any Price Fund Adviser has current or prospective business dealings including portfolio companies, unless such entertainment is in full compliance with the policy on entertainment as set forth in the Group Code.

------

**Gifts.** Accept any gifts, except as permitted by the Group Code.

**Improper Personal Influence.** Use his or her personal influence or personal relationships improperly to influence investment decisions, brokerage allocations or financial reporting by the Price Funds to the detriment of any one or more of the Price Funds.

**Taking Action at the Expense of a Price Fund.** Cause a Price Fund to take action, or fail to take action, for the personal benefit of the Covered Officer rather than for the benefit of one or more of the Price Funds.

**Misuse of Price Funds' Transaction Information.** Use knowledge of portfolio transactions made or contemplated for a Price Fund or any other clients of the Price Fund Advisers to trade personally or cause others to trade in order to take advantage of or avoid the market impact of such portfolio transactions; and in connection with Price ETFs that do not disclose portfolio holdings daily, use knowledge of pending changes to an ETF's proxy portfolio holdings for such purposes.

**Outside Business Activities.** Engage in any outside business activity that detracts from a Covered Officer's ability to devote appropriate time and attention to his or her responsibilities to a Price Fund.

**Service Providers.** Excluding Group and its affiliates, have any ownership interest in, or any consulting or employment relationship with, any of the Price Funds' service providers, except that an ownership interest in public companies is permitted

**Receipt of Payments.** Have a direct or indirect financial interest in commissions, transaction charges, spreads or other payments paid by a Price Fund for effecting portfolio transactions or for selling or redeeming shares other than an interest (such as compensation or equity ownership) arising from the Covered Officer's employment by Group or any of its affiliates.

**Service as a Director or Trustee.** Serve as a director, trustee or officer of any public or private company or a non-profit organization that issues securities eligible for purchase by any of the Price Funds, unless approval is obtained as required by the Group Code.

**IV. Covered Officers' Specific Obligations and Accountabilities.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. Disclosure Requirements and Controls.** Each Covered Officer must familiarize himself or herself with the disclosure requirements (Form N-lA registration statement, proxy (Schedule 14A), shareholder reports, Forms N-CEN, N-CSR, etc.) applicable to the Price Funds and the disclosure controls and procedures of the Price Fund and the Price Fund Advisers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. Compliance with Applicable Law.** It is the responsibility of each Covered Officer to promote compliance with all laws, rules and regulations applicable to the Price Funds and the Price Fund Advisers. Each Covered Officer should, to the extent appropriate within his or her area of responsibility, consult with other officers and employees of the Price Funds and the Price Fund Advisers and take other appropriate steps with the goal of promoting full, fair, accurate, timely and understandable disclosure in the reports and documents the Price Funds file with, or submit to, the SEC, and in other public

------

communications made by the Price Funds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C. Fair Disclosure.** Each Covered Officer must not knowingly misrepresent, or cause others to misrepresent, facts about a Price Fund to others, whether within or outside the Price organization, including to the Price Fund's directors and auditors, and to governmental regulators and self-regulatory organizations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D. Initial and Annual Affirmations.** Each Covered Officer must:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Upon adoption of the Price Funds S-O Code (or thereafter, as applicable, upon becoming a Covered Officer), affirm in writing that he or she has received, read, and understands the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Annually affirm that he or she has complied with the requirements of the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**E. Reporting of Material Violations of the Price Funds S-O Code.** If a Covered Officer becomes aware of any material violation of the Price Funds S-O Code or laws and governmental rules and regulations applicable to the operations of the Price Funds, he or she must promptly report the violation **("Report")** to the Chief Compliance Officer of the Price Funds **("CCO").** Failure to report a material violation will be considered itself a violation of the Price Funds S-O Code. The CCO is identified in the attached **Exhibit B.**

It is the Price Funds' policy that no retaliation or other adverse action will be taken against any Covered Officer or other employee of a Price Fund, a Price Fund Adviser or their affiliates based upon any lawful actions of the Covered Officer or employee with respect to a Report made in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**F. Annual Disclosures.** Each Covered Officer must report, at least annually, all affiliations or other relationships as called for in the "Annual Compliance Certification" for T. Rowe Price Group.

**V. Administration of the Price Funds S-O Code.** The Ethics Committee is responsible for administering the Price Funds S-O Code and applying its provisions to specific situations in which questions are presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. Waivers and Interpretations.** The Chairperson of the Ethics Committee has the authority to interpret the Price Funds S-O Code in any particular situation and to grant waivers where justified, subject to the approval of the Joint Audit Committee of the Price Funds. All material interpretations concerning Covered Officers will be reported to the Joint Audit Committee of the Price Funds at its next meeting. Waivers, including implicit waivers, to Covered Officers will be publicly disclosed as required in the Instructions to N-CSR. Pursuant to the definition in the Regulations, an implicit waiver means a Price Fund's failure to take action within a reasonable period of time regarding a material departure from a provision of the Price Funds S-O Code that has been made known to an "executive officer" (as defined in Rule 3b-7 under the Securities Exchange Act of 1934) of a Price Fund. An executive officer of a Price Fund includes its president and any vice-president in charge of a principal business unit, division or function.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. Violations/Investigations.** The following procedures will be followed in

------

investigating and enforcing the Price Funds S-O Code:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The CCO will take or cause to be taken appropriate action to investigate any potential or actual violation reported to him or her.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The CCO, after consultation if deemed appropriate with Outside Counsel to the Price Funds, will make a recommendation to the appropriate Price Funds Board regarding the action to be taken with regard to each material violation. Such action could include any of the following: a letter of censure or suspension, a fine, a suspension of trading privileges or termination of officership or employment. In addition, the violator may be required to surrender any profit realized (or loss avoided) from any activity that is in violation of the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Investigations of Whistleblower complaints related to Price Funds will be handled in accordance with the T. Rowe Price Global Whistleblower Policy.

**VI. Amendments to the Price Funds S-O Code.** Except as to the contents of **Exhibit A and Exhibit B,** the Price Funds S-O Code may not be materially amended except in written form, which is specifically approved or ratified by a majority vote of each Price Fund Board, including a majority of the independent directors on each Board.

**VII. Confidentiality.** All reports and records prepared or maintained pursuant to the Price Funds S-O Code will be considered confidential and shall be maintained and protected accordingly. Except as otherwise required by law, the Price Funds S-O Code or as necessary in connection with regulations under the Price Funds S-O Code, such matters shall not be disclosed to anyone other than the directors of the appropriate Price Fund Board, Outside Counsel to the Price Funds, members of the Ethics Committee and the CCO and authorized persons on his or her staff.

Adoption Date: 10/22/03

Last Revised: 05/11/2022 (Exhibit B revised)

------

## Exhibit A
**Persons Covered by the Price Funds and** 

**Price ETFs S-O Code of Ethics** 

David Oestreicher, Executive Vice President and Principal Executive Officer

Alan S. Dupski, Treasurer and Principal Financial Officer

## Exhibit B
Dino Capasso, Chief Compliance Officer